Oncogene (journal)
Oncogene is a peer-reviewed scientific journal that publishes research articles related to the field of oncology. The journal focuses on the cellular and molecular pathways of cancer cells, and its primary aim is to publish original research, reviews, and commentaries that elucidate the molecular mechanisms responsible for cancer development and progression.
History[edit | edit source]
The journal Oncogene was first published in 1987. Since its inception, it has been a leading source of information for researchers in the field of oncology. The journal is published by the Nature Publishing Group, a division of Springer Nature, which is known for its high-quality scientific publications.
Scope[edit | edit source]
Oncogene covers a broad range of topics related to cancer research, including but not limited to, the molecular basis of cancer, cell cycle regulation, cell growth, apoptosis, cell differentiation, DNA repair, genetic instability, microRNAs, epigenetics, cancer genetics, cancer genomics, cancer proteomics, cancer immunology, cancer stem cells, metastasis, angiogenesis, cancer therapeutics, and cancer prevention.
Impact Factor[edit | edit source]
The Impact factor of Oncogene is a measure of the frequency with which the average article in the journal has been cited in a particular year. As of 2020, the journal has an impact factor of 7.971, indicating its significant influence in the field of oncology.
Editorial Board[edit | edit source]
The editorial board of Oncogene consists of eminent scientists and researchers from around the world, who are experts in various aspects of oncology. The board is responsible for maintaining the high scientific standards of the journal and ensuring that only the most significant and rigorous research is published.
Submission and Review Process[edit | edit source]
Oncogene follows a stringent peer review process to ensure the quality and validity of the research it publishes. Manuscripts submitted to the journal are initially screened by the editorial team and those deemed suitable are sent for review to at least two independent experts in the field.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
